The Vietnamese pharmaceutical sector has witnessed a major ownership transition at Imexpharm Pharmaceutical JSC (HoSE: IMP). Following a successful public tender offer, Lian SGP Holding Pte. Ltd. has emerged as the dominant shareholder, securing controlling interest in the company.
Transaction details and ownership shift
Lian SGP Holding acquired 104.5 million IMP shares from 109 individual and institutional investors. At a tender price of 57,400 VND per share, the transaction value is estimated at approximately 6,000 billion VND. This move brings Lian SGP’s total ownership to 67.87% of Imexpharm’s charter capital.
The deal marks the exit of key shareholders from the SK Group (South Korea) ecosystem, which significantly reduced their holdings. Concurrently, members of Imexpharm’s senior management also registered to divest portions of their shares for personal financial balancing.
Investor profile and strategic vision
The acquiring entity, Lian SGP Holding, is a wholly-owned subsidiary of Livzon Pharmaceutical Group, a Chinese industry giant established in 1985. Ranked among the top 25 pharmaceutical firms in China, Livzon operates in over 30 countries, including the US, EU, and Japan.
Moving forward, the new leadership aims to steer Imexpharm toward several key objectives:
-
Maintaining operational stability while expanding high-tech product lines under EU-GMP standards.
-
Achieving the 2026 financial targets of 3,200 billion VND in revenue (9.8% growth) and 502 billion VND in pre-tax profit (12.5% growth).
-
Strengthening the brand’s footprint in Northern Vietnam by optimizing pharmacy chain distribution networks.